CVS to pay $440M to settle Omnicare billing allegations

CVS Health and its Omnicare unit will pay $440 million to resolve allegations that the senior-care pharmacy improperly billed the government for medications. The settlement, announced Monday, resolves a whistleblower lawsuit filed under the False Claims Act.

The company will record the charge in the current quarter. CVS said it had set aside reserves and admitted no wrongdoing. The payment covers claims that Omnicare submitted for drugs that were not medically necessary or lacked proper documentation. The case had been pending for several years.

For CVS, the settlement removes a legal distraction at a time when the healthcare giant faces other pressures. Its health insurance unit, Aetna, is wrestling with higher medical costs. Retail pharmacy foot traffic has slowed, and reimbursement rates are tightening. The trial risk included the possibility of treble damages under the False Claims Act, making the settlement a cap on exposure.

The $440 million payment is manageable against CVS's scale. The company generated $357 billion in revenue last year. The charge represents roughly 0.12% of that figure. Still, the cost lands in a quarter where margins are already under strain from medical-cost trends in the Aetna business. Any additional pressure on earnings matters when the market is focused on cost control.

CVS carries an Alpha Score of 60, a Moderate rating, reflecting mixed operational performance and an elevated debt load. The settlement does not change that picture. The company's fundamental challenges – managing pharmacy volume and keeping insurance costs in check – remain. More detail on the stock's risk profile is available on its CVS stock page.

The court must still approve the deal. A hearing is expected within 60 days.